TrialThe New England journal of medicine2020
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
727 papers cite itlatest 60 shown
this paperpooled ittrialcites it